• Pifithrin-α: p53 Control in Ferroptosis Research

  2026-09-04

  Pifithrin-α is a p53 inhibitor that helps distinguish p53-dependent ferroptosis from general oxidative injury. This article translates maternal deltamethrin neurotoxicity findings into rigorous assay decisions, controls, and interpretation strategies.

• Cytochalasin D: Actin Polymerization Inhibitor

  2026-09-04

  Cytochalasin D is an actin polymerization inhibitor that disrupts cytoskeletal remodeling and actin-dependent cellular transport. Product information reports a 25 nM IC50 and typical cell-culture use at 0.2–0.5 μg/mL, while ocular nanoparticle research supports its use as a mechanistic perturbation tool rather than a standalone uptake assay.

• CX-5461 RNA Polymerase I Inhibitor Workflows

  2026-09-03

  CX-5461 is a practical RNA polymerase I inhibitor for connecting rRNA transcription stress with DNA damage, senescence, autophagy, and mitotic catastrophe in solid tumor models. This workflow-oriented guide covers dosing, orthogonal readouts, cisplatin-combination experiments, and troubleshooting for reproducible cancer research.

• Bufuralol Hydrochloride in Human Organoid PK

  2026-09-03

  Bufuralol hydrochloride provides a practical pharmacological perturbation for testing β-adrenergic signaling alongside absorption, transporter, and CYP3A activity in human iPSC-derived intestinal models. This guide translates the latest organoid workflow into dosing, controls, and troubleshooting steps while clearly separating established evidence from assay-development recommendations.

• Dihydrotestosterone (DHT) Workflows for AR Research

  2026-09-02

  Build reproducible DHT experiments that connect androgen receptor signaling with EGFR, ERBB2, AKT, and muscle phenotypes. This guide combines dose-controlled cell assays, ALS model considerations, and a state-aware workflow inspired by a distinct SSC meiosis study.

• Cyclosporin A (B1922): Practical Lab Guide

  2026-09-02

  Cyclosporin A (SKU B1922) provides a practical cyclophilin and calcineurin-NFAT signaling inhibitor workflow for immunosuppression, apoptosis modulation, and related cell or animal research. It is water-insoluble, so it should not be used directly in aqueous formulations without validated solvent handling, and the dossier does not establish a universal dose or protocol for every model.

• Eltanexor: A Mechanism-First XPO1 Guide

  2026-09-01

  Eltanexor and KPT-8602 provide a powerful way to study how XPO1-dependent nuclear export controls cancer-cell survival. This mechanism-first guide connects cargo localization, Wnt/β-catenin biology, hematologic models, and practical assay design.

• ML385 Workflows for NRF2 Pathway Research

  2026-09-01

  ML385 enables controlled NRF2 inhibition across cancer, ferroptosis, and oxidative-stress assays. This practical guide connects cell-based target engagement with the reference study’s in vivo neuroprotection model while emphasizing dosing discipline, controls, and interpretation limits.

• JNJ-26854165: Reading the p53 Response

  2026-08-31

  JNJ-26854165 (Serdemetan) is an HDM2-directed research compound for studying p53-linked growth inhibition, apoptosis, and radiosensitization. This article presents an assay interpretation framework that separates proliferative arrest from true cell killing, improving the design of cancer research workflows.

• Nutlin-3a in GBM: Linking p53 to Ferroptosis

  2026-08-31

  Discover how Nutlin-3a, a potent MDM2 inhibitor, can support a causal assay strategy connecting p53 pathway activation with ferroptosis and migration in glioblastoma. This article translates a key miR-18a/ALOXE3 study into practical experimental decision-making without overstating clinical relevance.

• LG 101506: RXR Modulator Workflow

  2026-08-30

  LG 101506 provides a practical chemical perturbation point for RXR signaling pathway research, with applications spanning nuclear receptor biology, tumor-cell phenotyping, and immunometabolic assays. This workflow shows how to connect RXR modulation with the RBMS1–B4GALT1–PD-L1 biology described in triple-negative breast cancer without overstating an untested mechanism.

• Tariquidar (XR9576) in Viscosity-Driven Resistance

  2026-08-29

  Use Tariquidar (XR9576) to separate P-glycoprotein-mediated drug efflux from the mechanical signals that make tumor cells resistant. This workflow combines controlled extracellular viscosity, transporter inhibition, fluorescent accumulation assays, and mechanistic readouts for more defensible cancer chemoresistance studies.

• Decitabine: Practical Epigenetic Research Workflows

  2026-08-28

  Decitabine enables controlled DNA hypomethylation, tumor suppressor gene reactivation, and immune-focused assay design across hematopoietic and solid tumor models. This guide translates its mechanism into practical dosing, methylation, transcriptomic, and antigen-presentation workflows while highlighting limitations that prevent overinterpretation.

• Eltanexor (KPT-8602) Experimental Workflow

  2026-08-28

  Build a reproducible Eltanexor workflow that connects XPO1-dependent nuclear retention with viability, apoptosis, and Wnt/β-catenin readouts. The approach supports acute myeloid leukemia research while extending mechanistic testing into colorectal cancer cells, organoids, and chemoprevention models.

• SP2509: An Assay-First LSD1 Strategy

  2026-08-27

  SP2509 is a selective Lysine-specific demethylase 1 antagonist for dissecting histone-demethylation mechanisms in acute myeloid leukemia. This article presents an assay-first framework linking LSD1 inhibition, promoter-specific H3K4 methylation, AML differentiation, apoptosis, and cross-domain epigenetic interpretation.

8618 records 2/575 page Previous Next 12345 下5页 Last page